Trials / Completed
CompletedNCT00115570
Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents
Efficacy and Safety of Insulin Glulisine Compared With Insulin Lispro in Children and Adolescents With Type 1 Diabetes Mellitus: A 26 Week, Multicenter, Open, Parallel Clinical Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 572 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 4 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if insulin glulisine (Apidra) is as safe and effective a rapid acting insulin as insulin lispro (Humalog) in children and adolescents with type 1 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin glulisine | Subcutaneous injection |
| DRUG | insulin lispro | Subcutaneous injection |
| DRUG | insulin glargine | Subcutaneous injection once daily |
| DRUG | NPH insulin | subcutaneous injection twice daily |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2005-06-24
- Last updated
- 2016-05-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00115570. Inclusion in this directory is not an endorsement.